US4935449A
(en)
*
|
1988-08-04 |
1990-06-19 |
Merrell Dow Pharmaceuticals Inc. |
N-2,3-butadienyl tri- and tetraaminoalkane derivatives
|
FR2782007B1
(fr)
*
|
1998-08-05 |
2001-02-23 |
Centre Nat Rech Scient |
Utilisation des calix(n)arenes pour le traitement des maladies fibrotiques
|
US20030114410A1
(en)
|
2000-08-08 |
2003-06-19 |
Technion Research And Development Foundation Ltd. |
Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
|
FR2855969B1
(fr)
*
|
2003-06-13 |
2012-11-30 |
Coletica |
Stimulation de l'activite d'une isoforme de lysyl oxydase pour lutter contre certaines pathologies dues a une elastogenese incomplete, absente ou desorganisee
|
FR2855968B1
(fr)
|
2003-06-13 |
2012-11-30 |
Coletica |
Stimulation de la synthese et de l'activite d'une isoforme de la lysyl oxydase-like loxl pour stimuler la formation de fibres elastiques
|
WO2005069975A2
(en)
|
2004-01-23 |
2005-08-04 |
Massachusetts Eye & Ear Infirmary |
Lysyl oxidase-like 1 (loxl1) and elastogenesis
|
US20050276855A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Milos Chvapil |
Composition and method using local application of lipophilic lathyrogens sustained release formulations
|
US20060134172A1
(en)
*
|
2004-12-21 |
2006-06-22 |
Alcon, Inc. |
Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
|
US20070021365A1
(en)
*
|
2005-06-21 |
2007-01-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
|
US20070225242A1
(en)
*
|
2005-06-21 |
2007-09-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method and composition for treating and preventing tumor metastasis in vivo
|
JP5659014B2
(ja)
|
2007-08-02 |
2015-01-28 |
ジリード バイオロジクス,インク. |
線維症、腫瘍浸潤、血管新生及び転移の治療及び診断のための方法及び組成物
|
WO2010080769A2
(en)
|
2009-01-06 |
2010-07-15 |
Arresto Biosciences, Inc. |
Chemotherapeutic methods and compositions
|
KR20120054077A
(ko)
*
|
2009-08-21 |
2012-05-29 |
길리아드 바이오로직스, 인크. |
폐 섬유증 장애의 치료를 위한 방법 및 조성물
|
US20110207144A1
(en)
*
|
2009-08-21 |
2011-08-25 |
Derek Marshall |
In vitro screening assays
|
WO2011022670A1
(en)
*
|
2009-08-21 |
2011-02-24 |
Arresto Biosciences, Inc |
In vivo screening assays
|
BR112012008054A2
(pt)
|
2009-08-21 |
2017-05-23 |
Gilead Biologics Inc |
domínios catalíticos de lisil oxidase e loxl2
|
WO2011022710A1
(en)
*
|
2009-08-21 |
2011-02-24 |
Arresto Biosciences, Inc |
Therapeutic methods and compositions
|
RU2549684C2
(ru)
|
2010-02-04 |
2015-04-27 |
Джилид Байолоджикс, Инк. |
Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
|
CA2895782C
(en)
|
2012-12-21 |
2017-08-22 |
Gilead Calistoga Llc |
Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
|
NZ708870A
(en)
|
2012-12-21 |
2016-09-30 |
Gilead Calistoga Llc |
Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
|
PL3008053T3
(pl)
|
2013-06-14 |
2018-08-31 |
Gilead Calistoga Llc |
Inhibitory 3-kinazy fosfatydyloinozytolu
|
CA2931615A1
(en)
|
2013-11-26 |
2015-06-04 |
Gilead Sciences, Inc. |
Therapies for treating myeloproliferative disorders
|
EP3594215A1
(en)
|
2013-12-20 |
2020-01-15 |
Gilead Calistoga LLC |
Intermediate products in process methods for the preparation of phosphatidylinositol 3-kinase inhibitors
|
EP3083623A1
(en)
|
2013-12-20 |
2016-10-26 |
Gilead Calistoga LLC |
Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
|
US20160331754A1
(en)
|
2014-01-20 |
2016-11-17 |
Gilead Sciences, Inc. |
Therapies for treating cancers
|
JP6353082B2
(ja)
|
2014-06-11 |
2018-07-04 |
ギリアード サイエンシーズ, インコーポレイテッド |
心血管疾患を処置するための方法
|
TWI729644B
(zh)
|
2014-06-12 |
2021-06-01 |
美商西爾拉癌症醫學公司 |
N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
|
WO2015191754A2
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
EP3154960A1
(en)
|
2014-06-13 |
2017-04-19 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
WO2016094415A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Nephrogenesis, Llc |
Methods and drug therapies for patency of occluded blood vessels following angioplasty
|
TW201639573A
(zh)
|
2015-02-03 |
2016-11-16 |
吉李德科學股份有限公司 |
有關治療癌症之合併治療
|
SI3097102T1
(en)
|
2015-03-04 |
2018-02-28 |
Gilead Sciences, Inc. |
A TOOL RECEPTOR MODULING 4,6-DIAMINO-PYRIDO (3,2-D) PYRIMIDINE COMPOUNDS
|
JP6785804B2
(ja)
|
2015-06-23 |
2020-11-18 |
ギリアド サイエンシズ, インコーポレイテッド |
B細胞悪性腫瘍を治療するための組合せ療法
|
WO2017152062A1
(en)
|
2016-03-04 |
2017-09-08 |
Gilead Sciences, Inc. |
Compositions and combinations of autotaxin inhibitors
|
JP2019513737A
(ja)
|
2016-04-08 |
2019-05-30 |
ギリアード サイエンシーズ, インコーポレイテッド |
がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
|
UA126905C2
(uk)
|
2016-06-13 |
2023-02-22 |
Ай-Маб Байофарма Юес Лімітед |
Антитіло до pd-l1 та його застосування
|
US20180036289A1
(en)
|
2016-08-04 |
2018-02-08 |
Gilead Sciences, Inc. |
Cobicistat for use in cancer treatments
|
ES2826748T3
(es)
|
2016-09-02 |
2021-05-19 |
Gilead Sciences Inc |
Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
|
US10370342B2
(en)
|
2016-09-02 |
2019-08-06 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
WO2018057808A1
(en)
|
2016-09-23 |
2018-03-29 |
Gilead Sciences, Inc. |
Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
US20180133212A1
(en)
|
2016-11-03 |
2018-05-17 |
Gilead Sciences, Inc. |
Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
|
WO2018097977A1
(en)
|
2016-11-22 |
2018-05-31 |
Gilead Sciences, Inc. |
Crystalline forms of a phosphate complex of a bet inhibitor
|
CN112279918A
(zh)
|
2017-01-24 |
2021-01-29 |
天境生物科技(上海)有限公司 |
Cd73抗体及其用途
|
WO2018156901A1
(en)
|
2017-02-24 |
2018-08-30 |
Gilead Sciences, Inc. |
Inhibitors of bruton's tyrosine kinase
|
US10370381B2
(en)
|
2017-02-24 |
2019-08-06 |
Gilead Sciences, Inc. |
Inhibitors of bruton'S tyrosine kinase
|
BR112019021056B1
(pt)
|
2017-04-06 |
2022-11-22 |
Sustain Holdings, Llc |
Usos de uma composição que compreende um peptídeo mimético de colágeno para o tratamento ou a prevenção de uma doença, distúrbio ou ferida ocular
|
CN111051305A
(zh)
|
2017-08-22 |
2020-04-21 |
吉利德科学公司 |
治疗性杂环化合物
|
JP7098748B2
(ja)
|
2017-12-20 |
2022-07-11 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. |
Stingアダプタータンパク質を活性化するホスホン酸結合を有する2’3’環状ジヌクレオチド
|
CN111566120B
(zh)
|
2017-12-20 |
2023-09-29 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
|
PL3752501T3
(pl)
|
2018-02-13 |
2023-08-21 |
Gilead Sciences, Inc. |
Inhibitory pd-1/pd-l1
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
JP7242702B2
(ja)
|
2018-04-19 |
2023-03-20 |
ギリアード サイエンシーズ, インコーポレイテッド |
Pd-1/pd-l1阻害剤
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
EP3814272A4
(en)
|
2018-05-11 |
2022-03-02 |
Phosphorex, Inc. |
MICROPARTICLES AND NANOPARTICLES WITH NEGATIVE SURFACE CHARGES
|
EP3818052A1
(en)
|
2018-07-06 |
2021-05-12 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
US11186579B2
(en)
|
2018-07-06 |
2021-11-30 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
KR20230159715A
(ko)
|
2018-07-13 |
2023-11-21 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
AU2019373221B2
(en)
|
2018-10-31 |
2022-05-26 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity
|
SG11202103839UA
(en)
|
2018-10-31 |
2021-05-28 |
Gilead Sciences Inc |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
CA3129022C
(en)
|
2019-03-07 |
2023-08-01 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
EP3935066A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
KR20220031946A
(ko)
|
2019-04-22 |
2022-03-14 |
서스테인 홀딩스, 엘엘씨 |
콜라겐 펩타이드-기초 약제 조성물 및 이를 제조하고 사용하기 위한 장치 및 방법
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
CA3140708A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
KR20220032568A
(ko)
|
2019-06-25 |
2022-03-15 |
길리애드 사이언시즈, 인코포레이티드 |
Flt3l-fc 융합 단백질 및 사용 방법
|
KR20220085796A
(ko)
|
2019-10-18 |
2022-06-22 |
포티 세븐, 인코포레이티드 |
골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
|
US20210147568A1
(en)
|
2019-10-31 |
2021-05-20 |
Forty Seven, Inc. |
Anti-cd47 based treatment of blood cancer
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
EP4081305B1
(en)
|
2019-12-24 |
2024-09-18 |
Carna Biosciences, Inc. |
Diacylglycerol kinase modulating compounds
|
CN115087488A
(zh)
|
2020-02-14 |
2022-09-20 |
震动疗法股份有限公司 |
与ccr8结合的抗体和融合蛋白及其用途
|
AU2021264550A1
(en)
|
2020-05-01 |
2022-11-17 |
Gilead Sciences, Inc. |
CD73 inhibiting 2,4-dioxopyrimidine compounds
|
EP4173639A4
(en)
|
2020-06-26 |
2024-03-13 |
RaQualia Pharma Inc. |
METHOD FOR SELECTING A CANCER PATIENT WITH EFFECT OF COMBINATION THERAPY WITH RETINOID AND CANCER TREATMENT
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
KR20240025616A
(ko)
|
2021-06-23 |
2024-02-27 |
길리애드 사이언시즈, 인코포레이티드 |
다이아실글리세롤 키나제 조절 화합물
|
EP4359415A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
EP4359411A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
AU2022297367A1
(en)
|
2021-06-23 |
2023-12-07 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
KR20240091056A
(ko)
|
2021-10-28 |
2024-06-21 |
길리애드 사이언시즈, 인코포레이티드 |
피리디진-3(2h)-온 유도체
|
CN118201941A
(zh)
|
2021-10-29 |
2024-06-14 |
吉利德科学公司 |
Cd73化合物
|
CA3239528A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
AU2022417491A1
(en)
|
2021-12-22 |
2024-05-23 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
EP4245756A1
(en)
|
2022-03-17 |
2023-09-20 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
TW202345901A
(zh)
|
2022-04-05 |
2023-12-01 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
WO2024137852A1
(en)
|
2022-12-22 |
2024-06-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|